This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n29http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/genbank/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/uniprotkb/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/kegg-compound/
n28http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n22http://www.rxlist.com/cgi/generic/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/patent/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00005/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00005
rdf:type
n3:Drug
n3:description
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids
n3:dosage
n19:271B3EB8-363D-11E5-9242-09173F13E4C5 n19:271B3EB9-363D-11E5-9242-09173F13E4C5 n19:271B3EBA-363D-11E5-9242-09173F13E4C5 n19:271B3EBB-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# http://www.genome.jp/dbget-bin/www_bget?D00742 #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Etanercept; [updated 2014 Sept 24 cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=4&sid=eeea413d-1490-4efa-bf5d-71f40e1986a1%40sessionmgr111&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232781
n3:group
investigational approved
n3:halfLife
102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults
n3:indication
For treatment of severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis.
n3:manufacturer
n16:271B3EB2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n24:DB00005 n28:DB00005
dcterms:title
Etanercept
adms:identifier
n7:PA449515 n8:P20333 n9:D00742 n10:58406-455-04 n13:M32315 n14:C07897 n15:DB00005 n17:Etanercept
n3:mechanismOfAction
There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.
n3:packager
n16:271B3EB1-363D-11E5-9242-09173F13E4C5 n16:271B3EAF-363D-11E5-9242-09173F13E4C5 n16:271B3EB0-363D-11E5-9242-09173F13E4C5 n16:271B3EAD-363D-11E5-9242-09173F13E4C5 n16:271B3EAE-363D-11E5-9242-09173F13E4C5 n16:271B3EAC-363D-11E5-9242-09173F13E4C5
n3:patent
n4:7276477 n4:2123593 n4:2476934 n4:36755
n3:synonym
Tumor necrosis factor receptor 2 Tumor necrosis factor receptor type II p80 TNF-alpha receptor Tumor necrosis factor receptor superfamily member 1B precursor CD120b TNF-R2 p75
n20:hasAHFSCode
n29:92-00-00
n3:synthesisReference
Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, "Crystals of etanercept and methods of making thereof." U.S. Patent US07276477, issued October 02, 2007.
n25:hasConcept
n26:M0276736
foaf:page
n12:etanercept.html n22:etanercept.htm
n3:Molecular-Formula
n5:271B3EC0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B3EBF-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:L04AB01
n3:absorption
Bioavailability following sub-Q administration is approximately 60%. Peak plasma concentrations achieved within 69 hours.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
185243-69-0
n3:category
n3:clearance
* 160 +/- 80 mL/hr [RA patients]
n3:containedIn
n18:271B3EB3-363D-11E5-9242-09173F13E4C5 n18:271B3EB4-363D-11E5-9242-09173F13E4C5 n18:271B3EB6-363D-11E5-9242-09173F13E4C5 n18:271B3EB7-363D-11E5-9242-09173F13E4C5 n18:271B3EB5-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n5:271B3EBD-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n5:271B3EBE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B3EBC-363D-11E5-9242-09173F13E4C5